Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia

Patients with Chronic Lymphocytic Leukemia (CLL) have a 29- to 36-fold increased risk of invasive pneumococcal disease (IPD) compared to healthy adults. Therefore, most guidelines recommend vaccination with the 13-valent pneumococcal conjugated vaccine (PCV13) followed 2 months later by the 23-valen...

Description complète

Détails bibliographiques

Auteurs principaux:	Sabine Haggenburg, Hannah M. Garcia Garrido, Iris M. J. Kant, Hanneke M. Van der Straaten, Fransien De Boer, Sabina Kersting, Djamila Issa, Doreen Te Raa, Hein P. J. Visser, Arnon P. Kater, Abraham Goorhuis, Koen De Heer
Format:	Artigo
Langue:	Inglês
Publié:	MDPI AG 2023-07-01
Collection:	Vaccines
Sujets:	chronic lymphocytic leukemia pneumococcal vaccination immunogenicity antibody response
Accès en ligne:	https://www.mdpi.com/2076-393X/11/7/1201
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!